Peter Streibl – General Manager, Takeda Thailand
Peter Streibl, general manager of Takeda Thailand, highlights the importance of emerging markets for Takeda globally, as well as the 50–year long commitment of Takeda to Thailand and Thai patients.…
Takeda is a global pharmaceutical company that focuses on patients. By using innovation to drive business that created a remarkable history of over 235 years with inspiration to bring better health and a brighter future to everyone around the world. Takeda is present in Thailand since 1969.
Contact
57 Park Ecoplex Building, Wireless, Lumpini, Bangkok 10330
Tel: +66 0-2697-9300
Peter Streibl, general manager of Takeda Thailand, highlights the importance of emerging markets for Takeda globally, as well as the 50–year long commitment of Takeda to Thailand and Thai patients.…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the…
France has long been held up as Europe’s reference point for rare disease care – the first EU country with a national plan, a pioneer of coordinated expert networks, and…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
France’s minority government has forced through a Social Security & Healthcare Bill for 2026 containing EUR five billion in healthcare cuts. For the country’s beleaguered innovative pharma industry, this Bill…
From Hungary to Poland and now France, Nienke Feenstra has navigated some of Europe’s most complex healthcare landscapes. Today, as GM of Takeda France, she reflects on the country’s scientific…
In a pharma industry increasingly squeezed by falling legacy revenues, political pricing crackdowns, and the need to deliver the next wave of science at speed and scale, the right leadership…
Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs…
The latest stories from healthcare and the life sciences in the US. RFK Jr shares his 128 recommendations for addressing childhood chronic disease; Suspension of Capsida’s gene therapy clinical trial…
Bairbre Hickie, General Manager at Takeda, discusses the company’s strategic priorities in Switzerland, focusing on its commitment to bringing innovative treatments to patients and its role in advancing the life…
See our Cookie Privacy Policy Here
